SecSonar.com

Silence Therapeutics plc (SLN)

Silence Therapeutics plc at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Silence Therapeutics plc (SLN) is a Biotechnology company based in GB with a market capitalization of $320.4M. Revenue declined 98.7% year-over-year and free cash flow was negative at -$62.3M. This page tracks SLN's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

GB · 116 employees · IPO Sep 8, 2020

Valuation

Valuation & price

$6.10 · as of May 17, 2026 · -44.4% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

5.14

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$10.39$7.35$4.30Jul 25Dec 25Jul 26Jul 7, 25$5.73Jul 9, 25$6.48Jul 11, 25$6.44Jul 15, 25$6.49Jul 17, 25$6.22Jul 21, 25$6.17Jul 23, 25$6.15Jul 25, 25$6.34Jul 29, 25$6.20Jul 31, 25$6.16Aug 4, 25$5.95Aug 6, 25$5.32Aug 11, 25$5.09Aug 13, 25$5.85Aug 15, 25$5.49Aug 19, 25$5.52Aug 21, 25$5.46Aug 25, 25$5.06Aug 27, 25$5.20Aug 29, 25$4.81Sep 3, 25$5.01Sep 5, 25$5.69Sep 9, 25$5.21Sep 11, 25$4.88Sep 16, 25$4.85Sep 18, 25$5.03Sep 22, 25$5.04Sep 24, 25$5.14Sep 26, 25$5.54Sep 30, 25$5.19Oct 2, 25$5.20Oct 6, 25$5.19Oct 8, 25$5.25Oct 10, 25$5.00Oct 14, 25$5.84Oct 16, 25$6.59Oct 21, 25$7.40Oct 23, 25$7.25Oct 27, 25$7.14Oct 29, 25$7.23Oct 31, 25$7.16Nov 4, 25$6.51Nov 6, 25$6.45Nov 10, 25$6.35Nov 12, 25$6.73Nov 14, 25$6.83Nov 18, 25$6.75Nov 20, 25$6.35Nov 25, 25$6.35Nov 28, 25$6.74Dec 2, 25$6.25Dec 4, 25$7.13Dec 8, 25$6.91Dec 10, 25$6.26Dec 12, 25$6.32Dec 16, 25$6.27Dec 18, 25$6.23Dec 22, 25$6.45Dec 24, 25$6.14Dec 29, 25$6.31Jan 2, 26$6.15Jan 6, 26$5.73Jan 8, 26$5.80Jan 12, 26$5.90Jan 14, 26$5.87Jan 16, 26$5.04Jan 21, 26$5.68Jan 23, 26$5.67Jan 27, 26$5.11Jan 29, 26$4.96Feb 2, 26$4.90Feb 4, 26$4.30Feb 9, 26$4.51Feb 11, 26$4.33Feb 13, 26$4.45Feb 18, 26$4.86Feb 20, 26$5.00Feb 24, 26$5.33Feb 26, 26$5.42Mar 2, 26$5.98Mar 4, 26$5.78Mar 6, 26$6.23Mar 10, 26$6.27Mar 12, 26$6.97Mar 17, 26$6.91Mar 19, 26$6.38Mar 23, 26$5.78Mar 25, 26$5.47Mar 27, 26$4.93Mar 31, 26$5.27Apr 2, 26$5.94Apr 7, 26$5.60Apr 9, 26$5.80Apr 13, 26$6.01Apr 15, 26$7.28Apr 17, 26$7.53Apr 22, 26$7.97Apr 24, 26$7.70Apr 28, 26$7.70Apr 30, 26$7.31May 4, 26$7.29May 6, 26$7.36May 8, 26$6.97May 12, 26$6.79May 14, 26$7.13May 18, 26$6.23May 20, 26$6.24May 22, 26$6.20May 28, 26$6.86Jun 1, 26$6.53Jun 3, 26$6.41Jun 5, 26$6.17Jun 9, 26$6.01Jun 11, 26$6.68Jun 15, 26$7.00Jun 17, 26$6.76Jun 22, 26$7.53Jun 24, 26$9.16Jun 26, 26$10.14Jul 2, 26$10.39
$4.3052-week range$10.98
Loading valuation history…

Fundamentals

Key fundamentals

$320.4M

Market cap

-98.7%

Revenue growth (YoY)

61.5%

Gross margin

-$62.3M

Free cash flow (USD)

-$85M

Net debt

Net cash position

206.4%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$770.0KFY 2017$16.0KFY 2018$0.00FY 2019$244.0KFY 2020$5.5MFY 2021$12.4MFY 2022$17.7MFY 2023$25.4MFY 2024$43.3MFY 2025$559.0K
$770K$559K

Free cash flow by year

2016 → 2025

FY 2016$-10.6MFY 2017$-9.8MFY 2018$-16.9MFY 2019$1.7MFY 2020$-11.3MFY 2021$7.4MFY 2022$-57.6MFY 2023$-39.4MFY 2024$-67.9MFY 2025$-62.3M
-$10.6M-$62.3M

Gross margin by year

2021 → 2025

FY 202139.9%FY 202237.8%FY 202359.3%FY 202472.7%FY 202561.5%
39.9%61.5%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventCorporate Presentation UpdateJun 23, 2026Filing
  • 8-K eventAnnual General Meeting ResultsJun 16, 2026Filing
  • 8-K eventClinical Data PresentationJun 11, 2026Filing
  • FinancingSecurities RegistrationMay 18, 2026Filing
  • 8-K eventSales Agreement EstablishedMay 18, 2026Filing
  • 8-K eventEarnings ReleaseMay 7, 2026Filing
  • Quarterly report10-Q FiledMay 7, 2026Filing

Questions

Frequently asked questions

What is Silence Therapeutics plc's market cap?

Silence Therapeutics plc (SLN) has a market capitalization of $320.4M.

What is SLN's P/E ratio?

A meaningful P/E ratio is not available for SLN — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is SLN's price-to-book (P/B) ratio?

SLN trades at 5.14 times book value per share.

Are insiders buying SLN stock?

SEC Form 4 filings show no open-market insider buys at Silence Therapeutics plc in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

OABI

OmniAb, Inc.

$323.4M

FATE

Fate Therapeutics, Inc.

$317M

EVMN

Evommune, Inc.

$324.9M

BCYC

Bicycle Therapeutics plc

$325.5M

NAGE

Niagen Bioscience Inc

$311.8M

EDIT

Editas Medicine, Inc.

$331.4M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.